SUPN
Supernus Pharmaceuticals Inc
NASDAQ: SUPN · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$41.08
+0.29% today
Updated 2026-10-28
Market cap
$2.21B
P/E ratio
—
P/S ratio
2.66x
EPS (TTM)
$-1.92
Dividend yield
—
52W range
$38 – $60
Volume
0.8M
Supernus Pharmaceuticals Inc (SUPN) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$41.08
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.6B | $0.7B | $0.6B | $0.7B | $0.7B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -13.20%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.